Home / Market News / $CDNA

$CDNA news and market catalysts

The 22 most recent market catalysts affecting $CDNA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

22 catalysts 6 high impact 15 bullish 1 bearish Medical Diagnostics
Nov 11, 2026 Corporate Catalyst Neutral Impact 65
Piper Sandler Initiates Coverage of CareDx with Overweight Rating
Piper Sandler has initiated coverage on CareDx, Inc. with an 'Overweight' rating, indicating their belief that the stock will outperform its sector peers. This event is significant…
Nov 10, 2026 Corporate Catalyst Neutral Impact 55
CareDx CFO and COO Keith Kennedy Sells Shares Worth $4.8 Million
CareDx's CFO and COO, Keith Kennedy, sold a significant portion of his holdings, 61,961 shares, valued at $4.82 million. While insider selling can sometimes be perceived negatively…
Nov 5, 2026 Corporate Catalyst Neutral Impact 55
CareDx, Inc. Files Form 144
CareDx, Inc. disclosed that director Keith Kennedy filed a Form 144, which is a mandatory notice to the SEC when an insider intends to sell restricted or controlled securities. Thi…
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
CareDx Announces Publication of Third KOAR Analysis in Transplantation
CareDx announced the publication of its third KOAR registry analysis, which found a correlation between early post-transplant AlloSure Kidney dd-cfDNA levels and three-year graft o…
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
H.C. Wainwright Raises CareDx Price Target
H.C. Wainwright analyst Yi Chen raised the price target for CareDx (CDNA) from $46 to $90. This substantial increase in the price target typically signals a more bullish outlook on…
Nov 2, 2026 Corporate Catalyst Bearish Impact 55
Ark Invest Reduces Holdings in CareDx
Ark Invest reported selling $4.4 million of CareDx (CDNA) shares on November 2, 2026, as part of a broader portfolio adjustment. This transaction is significant because Ark Invest …
Oct 30, 2026 Corporate Catalyst Bullish Impact 65
BTIG Raises CareDx Price Target to $92
BTIG raised its price target for CareDx (CDNA) to $92 from $81, while reiterating its 'Buy' rating, following the company's Q3 financial results. This move signals increased analys…
Oct 29, 2026 Corporate Catalyst Bullish Impact 92
CareDx Reports Q3 2026 Financial Results and Raises Full-Year Guidance
CareDx announced Q3 2026 revenue of $139.4 million, significantly beating the FactSet consensus of $122.0 million, and reported an adjusted EPS of $0.70. This strong performance, h…
Oct 22, 2026 Corporate Catalyst Bullish Impact 65
CareDx Announces New KOAR Data at ASN Kidney Week 2026
CareDx announced new findings from its KOAR study at a major medical conference, ASN Kidney Week 2026. The data indicates that their AlloSure Kidney test can predict a nearly 3-fol…
Oct 19, 2026 Corporate Catalyst Bullish Impact 75
CareDx shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $65 to $80.
This headline represents a significant corporate catalyst for CareDx (CDNA). A maintained 'Buy' rating coupled with a 23% price target increase from a well-known firm like Canaccor…
Sep 24, 2026 Corporate Catalyst Bullish Impact 75
CareDx shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $60 to $74.
This headline represents a strong positive corporate catalyst for CareDx (CDNA). The maintained 'Buy' rating, coupled with a 23% increase in the price target, indicates that a prom…
Sep 24, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on CareDx, Raises Price Target to $74
BTIG analyst Mark Massaro maintained a 'Buy' rating for CareDx (CDNA) and raised the price target from $60 to $74. This action signals increased confidence from a prominent analyst…
Sep 2, 2026 Corporate Catalyst Neutral Impact 65
Canaccord Genuity Initiates Coverage On CareDx with Buy Rating, Announces Price Target of $65
Canaccord Genuity analyst Kyle Mikson has initiated coverage on CareDx (CDNA) with a 'Buy' rating and a $65 price target. This event is significant for CareDx as new analyst covera…
Aug 6, 2026 Corporate Catalyst Bullish Impact 65
BTIG Maintains Buy on CareDx, Raises Price Target to $60
BTIG analyst Mark Massaro has maintained a 'Buy' rating for CareDx (CDNA) and significantly raised the price target from $45 to $60. This upward revision in the price target signal…
Jul 31, 2026 Corporate Catalyst Bullish Impact 85
CareDx shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY2026 sales guidance above estimates.
This headline represents a strong corporate catalyst for CareDx, as positive earnings surprises and upward revisions to future guidance are typically met with significant investor …
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
CareDx shares are trading higher after the company reported better-than-expected Q2 financial results. Also, the company raised its FY2026 sales guidance above estimates.
This headline is a strong positive corporate catalyst for CareDx (CDNA). Better-than-expected Q2 results demonstrate current operational strength, while raising FY2026 sales guidan…
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
CareDx Q2 Adj. EPS $0.37 Beats $0.23 Estimate, Sales $131.948M Beat $114.044M Estimate
CareDx reported Q2 adjusted EPS of $0.37, significantly beating the $0.23 estimate, and sales of $131.948 million, surpassing the $114.044 million estimate. This represents a subst…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
CareDx Raises FY2026 Sales Guidance from $447.000M-$465.000M to $490.000M-$500.000M vs $455.924M Est
CareDx (CDNA) has updated its financial projections, raising its FY2026 sales guidance from an initial range of $447 million-$465 million to a new range of $490 million-$500 millio…
Jul 16, 2026 Corporate Catalyst Bullish Impact 85
Why Is CareDx Stock Skyrocketing Thursday?
CareDx announced that Medicare has finalized its Local Coverage Determination (LCD) for molecular testing used in solid organ transplant rejection monitoring. This is a crucial dev…
Jul 16, 2026 Corporate Catalyst Bullish Impact 65
BTIG Maintains Buy on CareDx, Raises Price Target to $45
BTIG analyst Mark Massaro has maintained a 'Buy' rating on CareDx (CDNA) and raised the price target from $28 to $45. This action indicates a strong vote of confidence from a promi…
Jul 16, 2026 Corporate Catalyst Bullish Impact 85
CareDx shares are trading higher after the company announced the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.
This headline is a significant positive catalyst for CareDx (CDNA) as the finalization of Medicare Local Coverage Determination (LCD) for molecular testing for solid organ allograf…
Jul 16, 2026 Corporate Catalyst Neutral Impact 75
CareDx Finalizes Medicare Local Coverage Determination Procedure Regarding Molecular Testing For Solid Organ Allograft Rejection
CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process for its molecular testing services used to detect solid organ allograft rejection. This…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.